Abstract
Background and objective: In the randomized controlled trial REMAP-CAP, it was shown that next to dexamethasone, the interleukin (IL)-6 receptor antagonist tocilizumab improves outcome, including survival in intensive care unit (ICU)-admitted coronavirus disease 2019 (COVID)-19 patients. Therefore tocilizumab has been added to many COVID-19 treatment guidelines. Because obesity is a risk factor for the development of severe COVID-19, concerns have been raised about overtreatment, as well as undertreatment, through weight-based dosing of tocilizumab. The currently applied dose of 8 mg/kg is based on the use of this drug for other indications, however it has not formally been investigated for COVID-19. In this study, the pharmacokinetics and pharmacodynamics of tocilizumab were investigated in ICU-admitted COVID-19 patients.
Methods: This was an open-label, single-centre, observational population pharmacokinetic and descriptive pharmacodynamic evaluation study. Enrolled patients, with polymerase chain reaction-confirmed COVID-19 were admitted to the ICU for mechanical ventilation or high flow nasal canula oxygen support. All patients were 18 years of age or older and received intravenous tocilizumab 8 mg/kg (maximum 800 mg) within 24 h after admission to the ICU and received dexamethasone 6 mg daily as concomitant therapy. For evaluation of the pharmacokinetics and pharmacodynamics of tocilizumab, all time points from day 0 to 20 days after dose administration were eligible for collection. A nonlinear mixed-effects model was developed to characterize the population pharmacokinetic parameters of tocilizumab in ICU-admitted COVID-19 patients. Covariate analysis was performed to identify potential covariates for dose individualization. For the development of alternative dosing schedules, Monte Carlo simulations using the final model were performed.
Results: Overall, 29 patients were enrolled between 15 December 2020 and 15 March 2021. A total of 139 tocilizumab plasma samples were obtained covering the pharmacokinetic curve of day 0 to day 20 after tocilizumab initiation. A population pharmacokinetic model with parallel linear and nonlinear clearance (CL) was developed and validated. Average CL was estimated to be 0.725 L/day, average volume of distribution (V d ) was 4.34 L, maximum elimination rate (V max ) was 4.19 μg/day, and concentration at which the elimination pathway is half saturated (K m ) was 0.22 μg/mL. Interindividual variability was identified for CL (18.9%) and V d (21%). Average area under the concentration versus time curve from time zero to infinity of the first dose (AUC inf 1st DOSE ) was 938 [±190] μg/mL*days. All patients had tocilizumab exposure above 1 μg/mL for at least 15 days. Bodyweight-based dosing increases variability in exposure compared with fixed dosing.
Conclusions: This study provides evidence to support a fixed dose of tocilizumab 600 mg in COVID-19 patients. Fixed dosing is a safe, logistically attractive, and drug expenses saving alternative compared with the current 8 mg/kg recommendation.
【초록키워드】 COVID-19, Dexamethasone, Randomized controlled trial, coronavirus disease, Open-label, intensive care, severe COVID-19, mechanical ventilation, Tocilizumab, obesity, nasal, outcome, risk factor, ICU, survival, Patient, pathway, age, receptor, distribution, Admission, patients, COVID-19 patients, pharmacokinetic, Evidence, Concentration, Analysis, dose, AUC, Safe, Support, Volume, REMAP-CAP, Older, first dose, Variability, average, indications, Final, COVID-19 treatment guidelines, covariate, oxygen support, intravenous tocilizumab, mixed-effects model, clearance, parameter, plasma sample, polymerase chain, IMPROVE, enrolled, shown, identify, performed, investigated, raised, linear, applied, was performed, provide, increase, added, fixed, saturated, concomitant therapy, dexamethasone 6 mg, dose administration, dosing schedules, eligible, elimination rate, fixed dose, 【제목키워드】 COVID-19, Population, Dosing, Result, Pharmacodynamic,